Scorpius Holdings Past Earnings Performance
Past criteria checks 0/6
Scorpius Holdings's earnings have been declining at an average annual rate of -13%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 24.8% per year.
Key information
-13.0%
Earnings growth rate
27.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 24.8% |
| Return on equity | -126.3% |
| Net Margin | -295.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Jan 13
Revenue & Expenses Breakdown
How Scorpius Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -30 | 22 | 0 |
| 30 Jun 24 | 10 | -30 | 23 | 0 |
| 31 Mar 24 | 10 | -32 | 25 | 0 |
| 31 Dec 23 | 7 | -40 | 26 | 0 |
| 30 Sep 23 | 2 | -51 | 26 | 0 |
| 30 Jun 23 | 2 | -50 | 25 | 0 |
| 31 Mar 23 | 1 | -45 | 23 | 0 |
| 31 Dec 22 | 0 | -41 | 20 | 0 |
| 30 Sep 22 | 1 | -38 | 19 | 0 |
| 30 Jun 22 | 1 | -36 | 18 | 0 |
| 31 Mar 22 | 2 | -36 | 16 | 0 |
| 31 Dec 21 | 2 | -35 | 17 | 0 |
| 30 Sep 21 | 2 | -28 | 14 | 0 |
| 30 Jun 21 | 2 | -29 | 17 | 0 |
| 31 Mar 21 | 3 | -27 | 16 | 0 |
| 31 Dec 20 | 3 | -26 | 15 | 0 |
| 30 Sep 20 | 4 | -23 | 14 | 0 |
| 30 Jun 20 | 4 | -20 | 9 | 0 |
| 31 Mar 20 | 3 | -21 | 9 | 0 |
| 31 Dec 19 | 3 | -20 | 9 | 0 |
| 30 Sep 19 | 3 | -22 | 9 | 0 |
| 30 Jun 19 | 5 | -19 | 9 | 0 |
| 31 Mar 19 | 6 | -18 | 9 | 0 |
| 31 Dec 18 | 6 | -16 | 7 | 0 |
| 30 Sep 18 | 4 | -14 | 6 | 0 |
| 30 Jun 18 | 3 | -13 | 6 | 0 |
| 31 Mar 18 | 2 | -12 | 6 | 0 |
| 31 Dec 17 | 2 | -12 | 6 | 0 |
| 30 Sep 17 | 1 | -12 | 6 | 0 |
| 30 Jun 17 | 1 | -11 | 5 | 0 |
| 31 Mar 17 | 0 | -11 | 5 | 0 |
| 31 Dec 16 | 0 | -13 | 4 | 0 |
| 30 Sep 16 | 0 | -16 | 4 | -2 |
| 30 Jun 16 | 0 | -19 | 5 | -1 |
| 31 Mar 16 | 0 | -21 | 4 | -1 |
| 31 Dec 15 | 0 | -20 | 5 | 0 |
| 30 Sep 15 | 0 | -17 | 4 | 2 |
| 30 Jun 15 | 0 | -15 | 4 | 3 |
| 31 Mar 15 | 0 | -13 | 4 | 3 |
| 31 Dec 14 | 0 | -12 | 4 | 3 |
| 30 Sep 14 | 0 | -10 | 4 | 3 |
| 30 Jun 14 | 0 | -10 | 4 | 3 |
| 31 Mar 14 | 0 | -8 | 3 | 3 |
Quality Earnings: SCPX is currently unprofitable.
Growing Profit Margin: SCPX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SCPX is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare SCPX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SCPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SCPX has a negative Return on Equity (-126.28%), as it is currently unprofitable.